HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

MRx102

has antineoplastic activity

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Phenanthrenes: 27
        MRx102: 3
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Phenanthrenes: 27
    - MRx102: 3

Experts

1.	Bertsch, Nicole L: 1 article (01/2019)
2.	Blackburn, Patrick R: 1 article (01/2019)
3.	Clayton-Smith, Jill: 1 article (01/2019)
4.	DDD Study: 1 article (01/2019)
5.	Hasadsri, Linda: 1 article (01/2019)
6.	Klee, Eric W: 1 article (01/2019)
7.	Nicola, Pantelis: 1 article (01/2019)
8.	Pichurin, Pavel N: 1 article (01/2019)
9.	Rankin, Julia: 1 article (01/2019)
10.	Rasmussen, Kristen J: 1 article (01/2019)

Related Diseases

1.	Lung Neoplasms (Lung Cancer) 11/01/2016 - "The purpose of this study was to evaluate MRx102 as a novel therapeutic for lung cancer. " 11/01/2016 - "Mice injected subcutaneously with H460 lung cancer cells were treated with MRx102 or carboplatin to determine the effect of MRx102 on tumor formation in comparison to standard treatment. " 11/01/2016 - "The triptolide derivative MRx102 inhibits Wnt pathway activation and has potent anti-tumor effects in lung cancer." 11/01/2016 - "We tested the effects of MRx102 treatment on migration and invasion of lung cancer cells using Transwell filters coated with fibronectin and Matrigel, respectively. "
2.	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 03/01/2012 - "In vivo, MRx102 greatly decreased leukemia burden and increased survival time in non-obese diabetic/severe combined immunodeficiency mice harboring Ba/F3-ITD cells. "
3.	Neoplasms (Cancer) 11/01/2016 - "The decrease in tumor formation by MRx102 in the patient-derived xenograft model was WIF1-dependent, demonstrating that MRx102 is a potent inhibitor of the Wnt pathway in low WIF1 expressing NSCLC patient tumors. " 11/01/2016 - "In vivo, NSCLC tumor formation and metastasis were greatly decreased by MRx102 treatment. " 11/01/2016 - "Mice injected subcutaneously with H460 lung cancer cells were treated with MRx102 or carboplatin to determine the effect of MRx102 on tumor formation in comparison to standard treatment. " 11/01/2016 - "The triptolide derivative MRx102 inhibits Wnt pathway activation and has potent anti-tumor effects in lung cancer."
4.	Neoplasm Metastasis (Metastasis) 11/01/2016 - "In vivo, NSCLC tumor formation and metastasis were greatly decreased by MRx102 treatment. "
5.	Intellectual Disability (Idiocy) 01/01/2019 - "Pathogenic variants in DDX3X have been shown to cause X-linked intellectual disability (ID) (MRX102, MIM: 300958). "

Related Drugs and Biologics

1.	Carboplatin (JM8)
2.	Fibronectins (Fibronectin)
3.	matrigel
4.	triptolide